Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (ZostavaxR) in individuals aged ≥ 70 years: A randomized study of a single dose vs. two different two-dose schedules

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 4, 2013, Pages 858-864

  Vesikari, Timo ^a   Hardt, Roland ^b   Rümke, Hans C ^c   Icardi, Giancarlo ^d   Montero, Jordi ^e   Thomas, Stéphane ^f   Sadorge, Christine ^f   Fiquet, Anne ^f,g  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b St Hildegardis Krankenhaus   (Germany)

^c University Vaccine Center Rotterdam Nijmegen   (Netherlands)

^d UNIVERSITY OF GENOA   (Italy)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f SANOFI PASTEUR   (France)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Aging; Herpes zoster vaccine; Randomized clinical trial; Two dose regimen; Varicella zoster virus; Zostavax

Indexed keywords

HERPES ZOSTER IMMUNOGLOBULIN; VARICELLA ZOSTER VACCINE;

AGE DISTRIBUTION; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HERPES ZOSTER; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE DRUG DOSE; OPEN STUDY; PAIN; PHASE 3 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; VIRUS IMMUNITY;

AGING; HERPES ZOSTER VACCINE; RANDOMIZED CLINICAL TRIAL; TWO-DOSE REGIMEN; VARICELLA ZOSTER VIRUS; ZISTAVAX®;

AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; LONGITUDINAL STUDIES; MALE; VACCINATION;

EID: 84877119728     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23412     Document Type: Article

References (40)

1. Johnson RW, Wasner G, Saddier P, Baron R. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging 2008; 25:991-1006; PMID:19021299; http://dx.doi.org/10.2165/0002512-200825120-00002.
2. Johnson RW. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination. Aging Clin Exp Res 2009; 21:236-43; PMID:19571648.
3. Yawn B P, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. [Erratum in: Mayo Clin Proc 2008; 83:255.]. Mayo Clin Proc 2007; 82:1341-9; PMID:17976353; http://dx.doi.org/10.4065/82.11. 1341.
4. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975; 25:571-5; PMID:1195231.
5. Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001; 32:1481-6; PMID:11317250; http://dx.doi.org/10.1086/320169.
6. Schmader K, Gnann JW Jr., Watson C P. The epide-miological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008; 197(Suppl 2):S207-15; PMID:18419399; http://dx.doi.org/10.1086/522152.
7. Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrami K, Gallagher WJ, Johnson R, et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003; 70(Suppl 1):S24-30; PMID:12627483; http://dx.doi.org/10.1002/jmv.10316.
8. Meister W, Neiss A, Gross G, Doerr HW, Höbel W, Malin J P, et al. A prognostic score for postherpetic neuralgia in ambulatory patients. Infection 1998; 26:359-63; PMID:9861560; http://dx.doi.org/10.1007/BF02770836.
9. Lydick E, Epstein RS, Himmelberger D, White CJ. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 1995; 45(Suppl 8):S52-3; PMID:8545021; http://dx.doi.org/10.1212/WNL.45.12-Suppl-8.S52.
10. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 2007; 23:490-6; PMID:17575488; http://dx.doi.org/10.1097/AJP.0b013e318065b6c9.
11. Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010; 8:37; PMID:20565946; http://dx.doi.org/10.1186/ 1741-7015-8-37.
12. Weinke T, Edte A, Schmitt S, Lukas K. Impact of herpes zoster and post-herpetic neuralgia on patients' quality of life: a patient-reported outcomes survey. Z Gesundh Wiss 2010; 18:367-74; PMID:21124645; http://dx.doi.org/10.1007/s10389-010-0323-0.
13. Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebenstein B, Sambhara S. Challenges for vaccination in the elderly. Immun Ageing 2007; 4:9; PMID:18072962; http://dx.doi.org/10.1186/1742-4933-4-9.
14. Arvin AM. Varicella-zoster virus. In Knipe DM, Howley PM, Eds. Fields Virology, 4th edn. Lippincott Williams & Wilkins, Philadelphia, PA, 2001: 2731-68.
15. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48(Suppl 1):S2-7; PMID:20510263; http://dx.doi.org/ 10.1016/S1386-6532(10)70002-0.
16. Gauthier A, Breuer J, Carrington D, Martin M, Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009; 137:38-47; PMID:18466661; http://dx.doi.org/10.1017/ S0950268808000678.
17. Strauss S, Oxman MN, Freedberg IM, Eisen AZ, Wolff K, et al., eds. Fitzpatrick's Dermatology in General Medicine. 5th ed. Vol 2. New York, NY: McGraw-Hill; 1999:2427-50.
18. Johnson RW, Wasner G, Saddier P, Baron R. Postherpetic neuralgia: epidemiology, pathophysi-ology and management. Expert Rev Neurother 2007; 7:1581-95; PMID:17997705; http://dx.doi.org/10.1586/14737175.7.11.1581.
19. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002; 18:350-4; PMID:12441828; http://dx.doi.org/10.1097/00002508-200211000-00002.
20. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004; 39:342-8; PMID:15307000; http://dx.doi.org/10.1086/421942.
21. Dworkin RH, Gnann JW Jr., Oaklander AL, Raja SN, Schmader KE, Whitley RJ. Diagnosis and assessment of pain associated with herpes zoster and posther-petic neuralgia. J Pain 2008; 9(Suppl 1):S37-44; PMID:18166464; http://dx.doi.org/10.1016/j.jpain.2007.10.008.
22. ®): a guide to its use in preventing herpes zoster and postherpetic neuralgia. Drugs Ther Perspect 2011; 27:1-5; http://dx.doi.org/10.2165/11206290-000000000-00000.
23. Levin MJ, Murray M, Rotbart HA, Zerbe GO, White CJ, Hayward AR. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992; 166:253-9; PMID:1321859; http://dx.doi.org/10.1093/infdis/166.2.253.
24. Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995; 45(Suppl 8):S41-6; PMID:8545018; http://dx.doi.org/10.1212/WNL.45.12-Suppl-8.S41.
25. Levin MJ, Barber D, Goldblatt E, Jones M, LaFleur B, Chan C, et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998; 178(Suppl 1):S109-12; PMID:9852987; http://dx.doi.org/10.1086/514264.
26. Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003; 188:1336-44; PMID:14593591; http://dx.doi.org/10.1086/379048.
27. Trannoy E, Berger R, Holländer G, Bailleux F, Heimendinger P, Vuillier D, et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 2000; 18:1700-6; PMID:10689152; http://dx.doi.org/10.1016/S0264-410X(99)00510-1.
28. Gilderman LI, Lawless J F, Nolen TM, Sterling T, Rutledge RZ, Fernsler DA, et al.; Zostavax Protocol 010 Study Group. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol 2008; 15:314-9; PMID:18077611; http://dx.doi.org/10.1128/CVI.00310-07.
29. Schmader KE, Levin MJ, Gnann JW Jr., McNeil SA, Vesikari T, Betts R F, et al. Efficacy, safety, and tolerabil-ity of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922-8; PMID:22291101; http://dx.doi.org/10.1093/cid/cir970.
30. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al.; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84; PMID:15930418; http://dx.doi.org/10.1056/NEJMoa051016.
31. Oxman MN, Levin MJ; Shingles Prevention Study Group. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis 2008; 197(Suppl 2):S228-36; PMID:18419402; http://dx.doi.org/10.1086/522159.
32. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, et al.; Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197:825-35; PMID:18419349; http://dx.doi.org/10.1086/528696.
33. Vermeulen JN, Lange JM, Tyring SK, Peters PH, Nunez M, Poland G, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine 2012; 30:904-10; PMID:22154769; http://dx.doi.org/10.1016/j.vac-cine.2011.11.096.
34. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75:800-2; http://dx.doi.org/10.1093/biomet/75.4. 800.
35. Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, et al.; Shingles Prevention Study Group. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med 2010; 152:545-54; PMID:20439572.
36. Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging 2010; 27:159-76; PMID:20104941; http://dx.doi.org/10.2165/10489140-000000000- 00000.
37. CPMP 1997 Note For Guidance On Good Clinical Practice. (CPMP/ICH/135/95), 1997. Accessed on 05 Jan 2011 at: http://www.ema.europa.eu/pdfs/human/ich/ 013595en.pdf
38. WMA 2010 World Medical Association Declaration Of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. Accessed on 05 Jan 2011 at: http://www.wma.net/en/30publications/10policies/b3/index.html
39. Krah DL, Cho I, Schofield T, Ellis RW. Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (Varivax) in children and adults. Vaccine 1997; 15:61-4; PMID:9041667; http://dx.doi.org/10. 1016/S0264-410X(96)00107-7.
40. Guenther LC. Herpes zoster and postherpetic neuralgia. Expert Review of Dermatology 2006; 1:607-18; http://dx.doi.org/10.1586/17469872.1.4.607.